Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
The Beta Secretase Enzyme BACE1 target for Alzheimer's Disease-Secret

The Beta Secretase Enzyme BACE1 target for Alzheimer's Disease-Secret

Vegad, Kunjal
Shah, Dhwani
Shah, Hirak

Paperback

Medical Reference

ISBN10: 6208011019
ISBN13: 9786208011017
Publisher: LAP Lambert Academic Publishing
Published: Aug 15 2024
Pages: 64
Weight: 0.23
Height: 0.15 Width: 6.00 Depth: 9.00
Language: English
Despite the consensus among seniors and primary care physicians on the importance of short cognitive assessments for dementia detection, only half of seniors have been assessed, with just 16 percent undergoing regular evaluations. Educational initiatives are available to increase the use of these assessments in primary care, according to Alzheimer's Association surveys.Alzheimer's disease (AD) pathogenesis involves oxidative stress/mitochondrial dysfunction, amyloid/tau toxicity, and cholinergic dysfunction. Among the therapeutic targets, Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is crucial due to its role in the amyloidogenic cleavage of APP, generating Amyloid β (Aβ). BACE1, a β-secretase, also cleaves substrates like neuregulin and the β2 subunit of the voltage-gated sodium channel, essential for brain development and function. BACE1 is modulated post-translationally by factors linked to both physiological and pathological functions. However, developing small molecule inhibitors for BACE1 has posed challenges for AD treatment.

Also from

Shah, Hirak

View All

Also in

Medical Reference

View All